BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
NEW YORK, January 10, 2024 – BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on January 4, 2024, it received a Foreign Delinquency Compliance Plan Alert Letter (the "Letter") from The Nasdaq Stock Market LLC ("Nasdaq"). In the Letter, the staff of Nasdaq notified the Company that it is not in compliance with Nasdaq Listing Rule 5250(c)(2), because it has not timely filed its Form 6-K for the period ended June 30, 2023 (the "Filing").
紐約，2024 年 1 月 10 日 — BeyondSpring Inc. 納斯達克股票代碼：BYSI）（“BeyondSpring” 或 “公司”）是一家全球臨床階段的生物製藥公司，專注於使用突破性的技術平台進行藥物發現和開發創新療法，以改善醫療需求未得到滿足的患者的臨床療效。該公司於2024年1月4日宣佈，它於2024年1月4日收到了納斯達克股票市場有限責任公司（“納斯達克股票市場有限責任公司”）的外國犯罪合規計劃提醒函（“信函”）”）。在信中，納斯達克工作人員通知公司，該公司不遵守納斯達克上市規則5250（c）（2），因爲它沒有及時提交截至2023年6月30日的6-K表格（“申報”）。
In accordance with Nasdaq Listing Rules, the Company has 60 calendar days to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, Nasdaq can grant the Company an exception of up to 180 calendar days from the Filing's due date, or until July 1, 2024, to regain compliance.
根據納斯達克上市規則，公司有60個日曆日的時間來提交恢復合規的計劃。如果納斯達克接受公司的計劃，納斯達克可以批准公司自申報截止日起最多180個日曆日的例外情況，或者直到2024年7月1日，以恢復合規。
The Letter has no immediate effect on the listing or trading of the Company's ordinary shares on Nasdaq. The Company's management is working diligently to complete the Filing as soon as practicably possible to regain compliance with the Nasdaq Listing Rule 5250(c)(2).
該信函對公司普通股在納斯達克的上市或交易沒有立即影響。公司管理層正在努力盡快完成申報，以恢復對納斯達克上市規則5250（c）（2）的遵守。
About BeyondSpring
關於 BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring's subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration with Eli Lilly. Learn more by visiting https://beyondspringpharma.com.
BeyondSpring (NASDAQ: BYSI) 是一家全球臨床階段的生物製藥公司，專注於開發創新療法，以改善醫療需求未得到滿足的患者的臨床療效。該公司正在推進其首創的主導資產Plinabulin，該資產是各種癌症適應症的直接抗癌藥物，用於預防化療引起的中性粒細胞減少症。它是 管道 還包括三項臨床前免疫腫瘤學資產。此外，BeyondSpring的子公司SEED Therapeutics利用專有的靶向蛋白質降解（TPD）藥物發現平台，並與禮來公司進行了初步的研發合作。通過訪問了解更多信息 https://beyondspringpharma.com。
Investor Contact:
投資者聯繫人：
IR@beyondspringpharma.com
IR@beyondspringpharma.com
Media Contact:
媒體聯繫人：
PR@beyondspringpharma.com
PR@beyondspringpharma.com
譯文內容由第三人軟體翻譯。